In Munich 🇩🇪 today with the @eular.org #PARE committee, working already on topics like the November Conference or 2026 EULAR Congress!

Very happy to see again #PARE highlights in the closing session of #EULAR2025. Michael Poelzl presented the #Highlights of the Patient and joint sessions presented by Peter Boyd, a 🧵

Wonderful to hear from our @eular.org 2025 Edgar Stene Prize winner, Yvonne Balvers, who focused on the challenges of everyday activities that able bodied individuals may dismiss, and the persistence of trauma from childhood-onset RMDs into adulthood #eular2025

Fantastic to see Sladjana, a STRATA-FIT patient research partner, presenting about the project and the evaluation of PRP involvement - partnership, communication, and support are critical #eular2025

Day 3 of #EULAR2025! 😴 We’ll discuss all things related to sleep & fatigue in this fascinating #PARE session 📍 C3 🕰️ 15:45-17:00 🗓️ Today! 👋🏼 See you there!

The disconnect between patient and HCP priorities in Sjogren’s Disease endpoint priorities, specifically for pain, fatigue, and QoL is evident #eular2025

Co-creation in practice: creating new clinical endpoints for primary Sjogren’s Disease between patient organisations, healthcare professionals, and industry professionals #eular2025

Support requests for patient organisations regarding roll-out of electronic health records… again highlights the need for integrated collaborative approaches between healthcare providers/payers and patient organisations #eular2025

At the #EULAR2025 #PARE Poster tour, full room!

Daniel Aletaha, President of EULAR, always knows how to make an entrance! #EULAR2025 is officially underway! 👏 @eular.org

Happy to be at #EULAR2025 in Barcelona!

IMPACT Trial Certolizumab in high-risk pregnancies (APS + LAC): • Complications: ↓ from 80% to 20% • Gestational age: ↑ from 24 to 36.5 weeks • Live births: ↑ from 38% to 93% Huge congratulations to Jane Salmon & team – truly transformative results!

🤔Missed any #RheumaPreg25 sessions? No worries! Join the highlights webinar on May 26. Contact @karenschreiber.bsky.social or @lauraandreoli.bsky.social to join the #ReHFaP mailing list 📩

Third and last day of #RheumaPreg25!

@karenschreiber.bsky.social has presented "Quo vadis" obstetric #APS 👇 #RheumaPreg25

Prof. Angela Tincani (Brescia, Italy) talks about "Implications of New Classification Criteria of APS" #RheumaPreg25

2️⃣ Second session "Beyond the clot: challenges in obstetric antiphospholipid syndrome", chaired by Nathalie Costedoat-Chalumeau and Karoline Mayer-Pickel! #RheumaPreg25 #APS #APSmatters #oAPS

Day 2 of #RheumaPreg25, we kickoff talking about including pregnant patients in clinical trials. Laura Andreoli kicks off @lauraandreoli.bsky.social by talking about pregnancy, medication, and the Future of Medical Research 👇

It was a pleasure to participate in the session "Inclusion of pregnant patients with chronic conditions in research and clinical trials" in #RheumaPreg25 Such an honor to exchange with these wonderful women and incredible experts! 😍

Day 2 of RheumaPreg 2025 is underway! Today’s sessions focus on clinical research in pregnancy, obstetric APS, neonatal lupus, immunosuppression during pregnancy, and hormonal influences in rheumatic diseases. Stay tuned for more insights and discussion.

Dr. Kazem Nouri: presents "Fertility Preservation in Rheumatic Diseases" #RheumaPreg25

Dr. Klara Rosta: "How to approach infertility in rheumatic diseases" #RheumaPreg25 @rheproat.bsky.social Reproductive Trends: - Women having children later (avg. 31 years) - Fertility peak: 20-35 years - Reproductive potential declines after 35 - Biotechnology expanding fertility options 📊

Bettina Toth from Med Uni Innsbruck @i-med.ac.at talks about “Ovarian reserve: current diagnostic and therapeutic options” #RheumaPreg25

Already in Vienna 🇦🇹 ready for #RheumaPreg25!